Detail

Keywords

Carcinoma, Basal Cell; Immunotherapy; Melanoma; Oncolytic Viruses

Research interests

I am a clinician scientist with a particular focus on oncolytic virotherapy and biomarker discovery for skin cancer. My research aims to identify and validate biomarkers that can predict patient response to novel therapies, with a strong emphasis on translational research, bridging laboratory discoveries to real-world clinical applications. In my clinical role, I serve as a sub-investigator in Phase II and III clinical trials for metastatic melanoma and non-melanoma skin cancers at the Medical University of Vienna.

Selected publications

1. Dorfer, S. et al. (2024) ‘BRAF Inhibition and UVB Light Synergistically Promote Mus musculus Papillomavirus 1-Induced Skin Tumorigenesis’, Cancers, 16(18), p. 3133. Available at: https://doi.org/10.3390/cancers16183133.
2. Ressler, J.M. et al. (2024) ‘DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic Melanoma’, Targeted Oncology, 19(2), pp. 263–275. Available at: https://doi.org/10.1007/s11523-024-01041-4.
3. Ressler, J.M. et al. (2023) ‘Myofibroblast stroma differentiation in infiltrative basal cell carcinoma is accompanied by regulatory T‐cells’, Journal of Cutaneous Pathology, 50(6), pp. 544–551. Available at: https://doi.org/10.1111/cup.14381.
4. Ressler, J.M. et al. (2021) ‘Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany’, Journal for ImmunoTherapy of Cancer, 9(2), p. e001701. Available at: https://doi.org/10.1136/jitc-2020-001701.